In some Western countries, the frequency and mortality of lung cancer are decreasing due to decades of public education and tobacco control policies, even though it still remains a major cause of mortality worldwide. Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
With #ASCO25 still fresh in our minds, touchONCOLOGY Editorial Board members Dr Fatemeh Ardeshir-Larijani (Emory School of Medicine, Atlanta, GA, USA) and Dr Gabirel Lenz (Hospital Regional Terezinha Gaio Basso, São Miguel Do Oeste, Brazil) reflect on their top key breakthroughs and take-aways from the conference in non-small cell lung cancer (NSCLC).
Expert insights on the practical application of immunotherapy in early-stage NSCLC
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.
Watch an expert discuss the key clinical questions surrounding currently approved RET inhibitors in NSCLC.
We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, ...
In this symposium, three lung cancer specialists share their insights on TROP2-targeted ADCs in NSCLC
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Dr Elene Mariamidze (Todua Clinic, Tbilisi) has built a career shaped by diverse mentorship and a commitment to patient-centered oncology. She reflects on invaluable lessons from global experts, the future of oncology, and practical advice for aspiring oncologists entering this challenging yet rewarding field.
In this short series of engaging videos, four leading oncology experts discuss current unmet needs in EGFRm NSCLC, the importance of MET diagnostic testing, and treatment options for non-oncogene-addicted NSCLC.
In this activity, watch leading oncology experts discuss recent consensus statements from near-global groups on the diagnosis, testing, and management of METex14 skipping NSCLC.
The US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for zongertinib (BI 1810631), a treatment for adults with advanced non-small cell lung cancer (NSCLC) characterized by HER2 (ERBB2) mutations who have undergone prior ...
Our Editorial Board supports our mission to advance medical knowledge and practice by ensuring the integrity, relevance and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of ...
Experts discuss the role of RAS mutations in solid tumours and how they may be targeted to improve outcomes.
Watch a lung cancer expert discuss the latest data for ADCs in NSCLC and their implications for clinical practice.
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.